Our Blog
Semaglutide was approved on June 04, 2021 by the U.S. Food and Drug Administration as a once a week injection for chronic weight management in adults with obesity or overweight with at least one weight – related condition. The safety and efficacy were studied in four 68 week trials. More than 2,600 patients received semaglutide for up to 68 weeks in these four studies. The average age at the start of the trial was 46 and 74% of the patients were female. Of the individuals receiving semaglutide injections lost an average of 12.4% of their initial body weight. There are side effects as with any medication and all patients are encouraged to consult with their health care provide before beginning semaglutide.
Serving you from the comfort of your home or on the go. We all have overloaded lives, and we want to help make seeing us as easy and convenient as possible. Our telehealth services do just that. You don’t have to worry about missing an appointment or arriving late. Simply click on the secure appointment link and connect with us.
